Studies have shown that a combination of Namenda (memantine) and one of the cholinesterase inhibitors can often be more effective than either type of drug by itself. Recent clinical trials indicate Axona in combination with either or both types of medicines can be even more effective.

Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease
Objective: At present, inhibition of cholinesterase is the treatment of choice for subjects with mild-to-moderate Alzheimer's disease (AD). Memantine, a noncompetitive antagonist at N-methyl-d-asparta
Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzhe...
First long-term study finds that treatment slows symptom progression, benefits last for years
Study confirms benefit of combination therapy for Alzheimer's disease Extended treatment with Alzheimer's disease drugs can significantly slow the rate at which the disorder advances, and combinati
First long-term study finds that treatment slows symptom progression, benefits l...
Long-Term Combination Alzheimer's Therapy Slows Decline CME
Continuing Medical Education course Release Date: September 30, 2008; Valid for credit through September 30, 2009 Credits Available Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™ for
http://www.medscape.com/viewarticle/581273
Long-term course and effectiveness of combination therapy in Alzheimer disease
OBJECTIVE: To compare the real-world clinical effectiveness and long-term clinical trajectory in patients with Alzheimer disease (AD) treated with combination (COMBO) therapy consisting of cholines
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC271854...
Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease
* Background: Patients using cholinesterase inhibitors (ChEIs) have a delay in nursing home (NH) admission compared with those who were not using the medication. This study was conducted to examin
Long-term effects of the concomitant use of memantine with cholinesterase inhibi...
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
Introduction Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer's disease (AD) when used together. This study assessed the efficacy and safety of combination
Memantine in patients with Alzheimer's disease receiving donepezil: new ana...
Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
Introduction There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progres
Persistent treatment with cholinesterase inhibitors and/or memantine slows clini...
Rivastigmine Monotherapy and Combination Therapy with Memantine in Patients with Moderately Severe Alzheimer's Disease
We investigated the efficacy and safety of rivastigmine alone and combined with memantine in Alzheimer's disease patients previously failing on donepezil or galantamine. This was a prospective, ope
Rivastigmine Monotherapy and Combination Therapy with Memantine in Patients with...
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease
OBJECTIVE: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer's disease (AD) and Parkinson's disease dementia.
Safety and tolerability of rivastigmine capsule with memantine in patients with ...
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy
Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be effective in dementia, including Alzheimer disease (AD). Therefore, its combination
Tolerability of memantine in combination with cholinesterase inhibitors in demen...
Trial of Memantine/Donepezil Paves the Way for Combination Therapy
22 January 2004. Combining memantine with an older, widely used AD drug further improves measures of cognition, global well-being, activities of daily living, and behavior in people with moderate to s
http://www.alzforum.org/new/detail.asp...